These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27890814)

  • 1. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Mattace Raso G; Avagliano C; Calignano A
    Pharmacol Res; 2017 May; 119():491-492. PubMed ID: 27890814
    [No Abstract]   [Full Text] [Related]  

  • 2. New preclinical model are required to discover neuroprotective compound in Parkinson's disease.
    Segura-Aguilar J
    Pharmacol Res; 2017 May; 119():490. PubMed ID: 27894922
    [No Abstract]   [Full Text] [Related]  

  • 3. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
    Morgan AH; Rees DJ; Andrews ZB; Davies JS
    Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 5. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical aspects of neuroprotection in Parkinson's disease.
    Przuntek H
    J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson's Disease.
    Das NR; Sharma SS
    CNS Neurol Disord Drug Targets; 2015; 14(8):1024-30. PubMed ID: 25808897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease.
    Zhang Z; Li G; Szeto SSW; Chong CM; Quan Q; Huang C; Cui W; Guo B; Wang Y; Han Y; Michael Siu KW; Yuen Lee SM; Chu IK
    Free Radic Biol Med; 2015 Jul; 84():331-343. PubMed ID: 25769424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible neuroprotective therapy for Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 13. Zonisamide: aspects in neuroprotection.
    Rösler TW; Arias-Carrión O; Höglinger GU
    Exp Neurol; 2010 Aug; 224(2):336-9. PubMed ID: 20450911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alpha-2 adrenergic receptors and Parkinson's disease].
    Bonnet AM
    Presse Med; 2002 Jul; 31(25):1193-5. PubMed ID: 12192732
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective and neurorestorative strategies for Parkinson's disease.
    Dawson TM; Dawson VL
    Nat Neurosci; 2002 Nov; 5 Suppl():1058-61. PubMed ID: 12403986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Effect of the Marine-Derived Compound 11-Dehydrosinulariolide through DJ-1-Related Pathway in In Vitro and In Vivo Models of Parkinson's Disease.
    Feng CW; Hung HC; Huang SY; Chen CH; Chen YR; Chen CY; Yang SN; Wang HD; Sung PJ; Sheu JH; Tsui KH; Chen WF; Wen ZH
    Mar Drugs; 2016 Oct; 14(10):. PubMed ID: 27763504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
    Carta AR; Simuni T
    Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatments in the early stage of Parkinson disease].
    Rascol O
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F77-84. PubMed ID: 18680822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.